ABILIFY
ABILIFY is an antipsychotic with the world's first dopamine D2 receptor partial agonist action, which was discovered by Otsuka. In Japan it was launched in 2006 for the treatment of schizophrenia and in 2012 obtained an additional indication for improvement of manic symptoms of bipolar disorder.
Sincerely Pharmaceutical Tech
Regards,
Client Success Team (CRM),
Please fill the all required fields....!!
Sincerely Packaging Labelling
